

# Prism Medico & Pharmacy Limited

CIN: L51109MH2002PLC206595

23/91, White Bungalow, Yashwant Nagar,  
Near Filmistan Studio & Patkar College,  
Opposite BMC School, Goregaon West,  
Mumbai-400062

Telephone no – 022 28733312

Email Id – investorgrievancewmcl@gmail.com

Date: 12/08/2017

To,

Department of Corporate Services,  
**BSE LIMITED**  
P. J. Towers, Dalal Street,  
Mumbai – 400 001.

**Scrip ID: 512217**

**Subject: Outcome of Board meeting for the quarter ending 30<sup>th</sup> June, 2017**

Dear Sir/Madam

Pursuant to Regulation 33 of SEBI (Listing obligation and Disclosure Requirement) Regulation, 2015 (Listing Regulation's), the Board of Directors of the company at its meeting held on **Saturday, 12<sup>th</sup> August, 2017 at D-118, Industrial area, Phase VII, Mohali-160059**, have approved and taken on record, inter alia, the unaudited financial result ( standalone) of the company for the **quarter ended 30<sup>th</sup> June, 2017**.

Further, we wish to inform you that as per **SEBI circular no. CIR/CFD/FAC/62/2016 dated 6<sup>th</sup> July, 2016**, the company has opted to submit unaudited standalone financial results for the quarter ended 30<sup>th</sup> June, 2017 with Ind-AS compliant financial results for the corresponding quarter ended 30<sup>th</sup> June, 2016. We hereby inform you that the company shall submit standalone financial results for the quarter ending on and after 30<sup>th</sup> September, 2017 as per above circular. A copy of the Results, as required under Regulation 33 of the Listing Regulation, is enclosed herewith


Kindly take the same on your record.

Thanking You,

Yours Truly,

For, **PRISM MEDICO AND PHARMACY LIMITED**

**For PRISM MEDICOS AND PHARMACY LTD.**



Authorized Signatory

**Jasjot Singh**  
Executive Director  
DIN: 01937631

# PRISM MEDICO AND PHARMACY LTD.

CIN : L51109MH2002PLC206595

## STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017

QUARTER ENDED (IN LAKHS)

PARTICULARS	QUARTER ENDED 30TH JUNE 2017	QUARTER ENDED 30TH. JUNE 2016
1 REVENUE FROM OPERATIONS	514.79	-
2 OTHER INCOME	-	-
3 TOTAL REVENUE	514.79	-
4 EXPENSES:		
PURCHASE OF STOCK-IN-TRADE	411.58	-
CHANGE IN INVENTORIES	79.00	-
EMPLOYEE BENEFIT EXPENSES	0.30	-
FINANCE COSTS	0.00	-
PAYMENT TO BSE	-	9.14
DEPRECIATION	0.51	-
OTHER EXPENSES	4.14	1.45
TOTAL EXPENSES	495.53	10.59
5 PROFIT BEFORE TAX	19.26	(10.59)
6 TAX EXPENSE:		
(1)CURRENT TAX	-	-
(2)DEFERRED TAX	-	-
7 PROFIT(LOSS) FOR THE PERIOD	19.26	(10.59)
8 OTHER COMPREHENSIVE INCOME, NET OF INCOME TAX	-	-
A) i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-
B) i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	-	-
Total Other Comprehensive income, net of income tax	-	-
9 TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	19.25897	-10.59
PAID UP EQUITY SHARE CAPITAL:		
10 (FACE VALUE RS. 10 EACH)	606.3428	199.2
11 EARNINGS PER EQUITY SHARE		
(1)BASIC	0.32	(0.53)
(2)DILUTED	0.32	(0.53)

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12th august, 2017.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.

3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

*[Signature]*  
Pragatishree S. S. S.

# PRISM MEDICO AND PHARMACY LTD.

CIN : L51109MH2002PLC206595


---

4. The Ind AS compliant financial results, pertaining to period ended June 30, 2016 have not been subject to limited review or audit as the same is not mandatory as per SEBI's circular CIR/CFD/FAC/62/2016, dated July 5, 2016. on account of implementation of Ind-AS by listed companies.

5. The statement does not include Ind AS compliant results for the preceding quarter and previous year ended March 31, 2017 as the same is not mandatory as per SEBI's circular dated July 5, 2016.

This reconciliation statement has been provided in accordance with circular CIR/CFD/FAC/62/2016 issued by SEBI dated July 5, 2016 on account of implementation of Ind-AS by listed companies.

**For and on behalf of Board of Prism medico  
and Pharmacy Limited**



Place : Mumbai

Date :

**Gursimran Singh**  
**Executive Director**  
**DIN: 02209675**

# PRISM MEDICO AND PHARMACY LTD.

CIN : L51109MH2002PLC206595

## STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017

PARTICULARS	QUARTER ENDED (IN LAKHS)	
	QUARTER ENDED 30TH JUNE 2017	QUARTER ENDED 30TH. JUNE 2016
1 REVENUE FROM OPERATIONS		
2 OTHER INCOME	1,210.48	-
3 TOTAL REVENUE	0.87	-
4 EXPENSES:	1,211.35	-
PURCHASE OF STOCK-IN-TRADE	847.37	-
CHANGE IN INVENTORIES	106.51	-
EMPLOYEE BENEFIT EXPENSES	4.70	-
FINANCE COSTS	7.74	-
COST OF MATERIAL CONSUMED	151.93	-
PAYMENT TO BSE	-	9.14
DEPRECIATION	8.23	-
OTHER EXPENSES	17.23	-
TOTAL EXPENSES	1,143.71	1.45
5 PROFIT BEFORE TAX		10.59
6 TAX EXPENSE:	67.64	(10.59)
(1) CURRENT TAX		-
(2) DEFERRED TAX		-
7 PROFIT (LOSS) FOR THE PERIOD	67.64	(10.59)
8 OTHER COMPREHENSIVE INCOME, NET OF INCOME TAX		
A) i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-
B) i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	-	-
Total Other Comprehensive income, net of income tax		
9 TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	67.64	-10.59
PAID UP EQUITY SHARE CAPITAL:		
10 (FACE VALUE RS. 10 EACH)	1606.3428	199.2
11 EARNINGS PER EQUITY SHARE		
(1) BASIC	0.42	(0.53)
(2) DILUTED	0.42	(0.53)

### Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12th august, 2017.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.

3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

*Pragmeesan Saji*

# PRISM MEDICO AND PHARMACY LTD.


CIN : L51109MH2002PLC206595

4. The Ind AS compliant financial results, pertaining to period ended June 30, 2016 have not been subject to limited review or audit as the same is not mandatory as per SEBI's circular CIR/CFD/FAC/62/2016, dated July 5, 2016. on account of implementation of Ind-AS by listed companies.

5. The statement does not include Ind AS compliant results for the preceding quarter and previous year ended March 31, 2017 as the same is not mandatory as per SEBI's circular dated July 5, 2016.

**This reconciliation statement has been provided in accordance with circular CIR/CFD/FAC/62/2016 issued by SEBI dated July 5, 2016 on account of implementation of Ind-AS by listed companies.**

**For and on behalf of Board of Prism medico  
and Pharmacy Limited**



**Gursimran Singh  
Executive Director  
DIN: 02209675**

Place : Mumbai

Date :